CN102631430B - Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102631430B CN102631430B CN2012101175413A CN201210117541A CN102631430B CN 102631430 B CN102631430 B CN 102631430B CN 2012101175413 A CN2012101175413 A CN 2012101175413A CN 201210117541 A CN201210117541 A CN 201210117541A CN 102631430 B CN102631430 B CN 102631430B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- hepatic fibrosis
- traditional chinese
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Traditional Chinese medicine composition for resisting hepatic fibrosis, which is prepared by the following traditional Chinese medical materials: rhubarb, scutellaria, and coptis according to the mass ratio of 2:1:1. The traditional Chinese medicine composition is prepared by decocting and extracting the rhubarb, the scutellaria, and the coptis in water, and concentrating the extraction solution. The pharmacodynamics experiment proves that: the traditional Chinese medicine composition can reduce the levels of the serum transaminases and the liver hydroxyproline in a hepatic fibrosis model rat, improve the hepatic inflammatory change, and reduce the hepar collagen deposition degree, and has the function of resisting the hepatic fibrosis pathologic change. A pharmaceutically acceptable carrier can be added to the traditional Chinese medicine composition to prepare a medicine for resisting the hepatic fibrosis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation method and application of anti-hepatic fibrosis, belong to technical field of Chinese medicines.
Background technology
Hepatic fibrosis is the developing common pathological process of various chronic hepatopathys, a variety of causes causes hepatic tissue inner cell epimatrix composition hyperplasia and abnormal deposition, and then cause that liver structure or dysfunction change, the state of an illness one step development, can form liver cirrhosis and cause liver function obstacle and exhaustion, the serious harm life and health.Delay even to reverse hepatic fibrosis, to the generation that reduces severe complication, to improve quality of life of patients significant.Therefore, the medicine of development anti-hepatic fibrosis, have obvious using value.
Hepatic fibrosis is a dynamic pathological process, occurring, develop with a plurality of stages of disappearing in have a plurality of links to influence each other.The tcm prescription composition is various, and the hepatic fibrosis of pathological changes complexity is had multipath, too many levels, multi-level combined influence, and is evident in efficacy, has broad application prospects.
Summary of the invention
Technical problem one to be solved by this invention is to provide a kind of Chinese medicine composition of anti-hepatic fibrosis, and technical problem two is to provide the preparation method and application of the Chinese medicine composition of this anti-hepatic fibrosis.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is as follows:
A kind of Chinese medicine composition of anti-hepatic fibrosis is that raw material is prepared from by Chinese crude drug Radix Et Rhizoma Rhei, Radix Scutellariae, Rhizoma Coptidis.
The Chinese medicine composition of described a kind of anti-hepatic fibrosis, for raw material be prepared from mass ratio by Chinese crude drug Radix Et Rhizoma Rhei, Radix Scutellariae, Rhizoma Coptidis at 2: 1: 1.
The preparation method of the Chinese medicine composition of described anti-hepatic fibrosis, is characterized in that, gets Chinese crude drug Radix Et Rhizoma Rhei, Radix Scutellariae, Rhizoma Coptidis; Decoct with water, concentrated decocting liquid forms.
The preparation method of the Chinese medicine composition of described a kind of anti-hepatic fibrosis, it is characterized in that, decoct with water 2 times, from the each 0.5-2 hour of boiling timing, decoction for the first time is 5-20 times of total quality of medicinal material with water quality, and decoction for the second time is 5-10 times of total quality of medicinal material with water quality; Merge finally decoction liquor twice, concentrated being prepared from.
The preparation method of the Chinese medicine composition of described a kind of anti-hepatic fibrosis, is characterized in that, decocts with water 2 times, and from each 1 hour of boiling timing, decoction for the first time was 10 times of total quality of medicinal material with water quality, and decocting for the second time is 8 of total quality of medicinal material with water quality; Merge finally decoction liquor twice, concentrated being prepared from.
Described Chinese medicine composition or described Chinese medicine composition and the application of pharmaceutically acceptable pharmaceutical carrier in preparing the medicine of anti-hepatic fibrosis.
Described pharmaceutical preparation can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent.Suitable filler comprises cellulose, mannitol, lactose and other similar filler; Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate; Suitable lubricant comprises, for example magnesium stearate; Suitable wetting agent comprises sodium lauryl sulphate.Described pharmaceutical preparation can be any pharmaceutically useful dosage form, the preferred oral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Can carry out coating to tablet in case of necessity.
Chinese medicine composition of the present invention is comprised of Radix Et Rhizoma Rhei, Radix Scutellariae, Rhizoma Coptidis, and Fang Zhongsan flavor medicine is the product in large bitter Great Cold, has clearing heat, purging intense-heat, removing dampness detoxicating functions.The inventor is surprised to find that the present composition has the effect of anti-hepatic fibrosis.In order to verify this fact, the inventor adopts N-nitrosodimethylamine (Dimethylnitrosamine, the Rat Liver Fibrosis Model of DMN) inducing, apply Chinese medicine composition 4.8 of the present invention and 9.6g crude drug/kg gastric infusion, result of the test shows, Chinese medicine composition of the present invention can reduce serum transaminase (ALT) activity and Liver hydroxyproline (Hyp) level, improves the liver inflammatory pathological change and alleviate the deposition of collagen type Ⅰ degree the Liver Fibrosis Model rat, has the effect of anti-hepatic fibrosis pathological changes.
Description of drawings
Fig. 1 is the impact of Chinese medicine composition of the present invention on the hepatic pathology variation of N-nitrosodimethylamine Liver Fibrosis Model rat.
Fig. 2 is the impact of Chinese medicine composition of the present invention on the deposition of collagen type Ⅰ of N-nitrosodimethylamine Liver Fibrosis Model rat.
In figure: N-represents normal group; M-represents model control group; XL-represents XIEXIN TANG 4.8g crude drug/kg group; XH-represents XIEXIN TANG 9.6g crude drug/kg group.
The specific embodiment
, below in conjunction with specific embodiments and the drawings, further set forth the present invention.These embodiment are interpreted as only being used for explanation the present invention rather than being used for limiting the scope of the invention.After the content of having read the present invention's record, those skilled in the art can make various changes or modifications the present invention, and these equivalences change and modification falls into the claims in the present invention book limited range equally.
Embodiment 1
Getting Chinese crude drug Radix Et Rhizoma Rhei 800 grams, Radix Scutellariae 400 grams, Rhizoma Coptidis 400 grams, decocting boils 2 times, from each 1 hour of boiling timing, decocting for the first time with water quality is 16kg (be total quality of medicinal material 10 times), decocting for the second time with water quality is 12.8kg (be total quality of medicinal material 8 times), merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Embodiment 2
Getting Chinese crude drug Radix Et Rhizoma Rhei 800 grams, Radix Scutellariae 400 grams, Rhizoma Coptidis 400 grams, decocting boils 2 times, from each 0.5 hour of boiling timing, decocting for the first time with water quality is 16kg (be total quality of medicinal material 20 times), decocting for the second time with water quality is 8kg (be total quality of medicinal material 5 times), merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Embodiment 3
Getting Chinese crude drug Radix Et Rhizoma Rhei 800 grams, Radix Scutellariae 400 grams, Rhizoma Coptidis 400 grams, decocting boils 2 times, from each 1 hour of boiling timing, decocting for the first time with water quality is 16kg (be total quality of medicinal material 10 times), decocting for the second time with water quality is 16kg (be total quality of medicinal material 10 times), merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Embodiment 4
Getting Chinese crude drug Radix Et Rhizoma Rhei 800 grams, Radix Scutellariae 400 grams, Rhizoma Coptidis 400 grams, decocting boils 2 times, from each 2 hours of boiling timing, decocting for the first time with water quality is 8kg (be total quality of medicinal material 5 times), decocting for the second time with water quality is 12.8kg (be total quality of medicinal material 8 times), merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Test example 1
Purpose: observe the impact of the rat liver fibrosis rat model that Chinese medicine composition of the present invention induces DMN.
Method: select male Wistar rat, the cleaning level, body weight 150～180g, supplied with by Shanghai Slac Experimental Animal Co., Ltd..Rat is divided into normal group (N) and model group at random, and model group is with DMN10 μ l/kg body weight dosage lumbar injection, and every day 1 time, weekly for three days on end, in totally 4 weeks, wherein the 1st week was injected 2/3 amount; Normal group lumbar injection equivalent normal saline.After 4 weeks of animal via becoming mould, rat model is divided at random model control group (M), the present invention and presses low (4.8g crude drug/kg), high (the dosage group of 9.6g crude drug/kg) of the Chinese medicine of embodiment 1 preparation, gastric infusion is totally 4 weeks, and normal group and model group wait the capacity normal saline.Measure rat blood serum glutamate pyruvate transaminase (ALT) and hepatic tissue hydroxyproline (Hyp) level after medication finishes, carry out hepatic tissue pathology dyeing, Picro-Sirius red chromoscopy.
Result: in Table 1, and Fig. 1,2.
The impact of table 1 Chinese medicine composition of the present invention active on the ALT of DMN Liver Fibrosis Model rat in hepatic tissue Hyp level (mean ± standard deviation, n=8)
*P＜0.05,
*Compare with model group P＜0.01.
In table: N-represents normal group; M-represents model control group; XL-represents XIEXIN TANG 4.8g crude drug/kg group; XH-represents XIEXIN TANG 9.6g crude drug/kg group.
The medicine for treatment of two dosage groups of Chinese medicine composition of the present invention can reduce rat blood serum glutamate pyruvate transaminase (in Table 1).Two dosage groups of Chinese medicine composition of the present invention also can reduce rat liver hydroxyproline content (in Table 1), hepatic tissue HE coloration result shows, there is more inflammatory cell infiltration the visible portal area of model group, a large amount of hypertrophy of fibroblast, the extensive degeneration of hepatocyte and necrosis; Two dosage group inflammatory cell infiltrations of Chinese medicine composition of the present invention and fibroblast proliferation obviously reduce, and hepatocellular degeneration and necrosis alleviate (seeing Fig. 1).Hepatic tissue Picro-Sirius red collagen staining result shows, the visible pseudolobuli formation in model group portal area, and see a large amount of collagen fiber depositions; Two dosage groups of Chinese medicine composition of the present invention have no pseudolobuli and form, and the collagen fiber deposition obviously reduces (seeing Fig. 2).
Conclusion: Chinese medicine composition of the present invention has the effect of anti-hepatic fibrosis pathological changes.
Claims (1)
- One kind by Chinese crude drug Radix Et Rhizoma Rhei, Radix Scutellariae, Rhizoma Coptidis in mass ratio 2:1:1 be the application of Chinese medicine composition in preparing the medicine of anti-hepatic fibrosis that raw material is made:The preparation method of the Chinese medicine composition of described anti-hepatic fibrosis is, raw material decocts with water 2 times, from the each 0.5-2 hour of boiling timing, decoction for the first time is 5-20 times of total quality of medicinal material with water quality, and decoction for the second time is 5-10 times of total quality of medicinal material with water quality; Merge finally decoction liquor twice, concentrated being prepared from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101175413A CN102631430B (en) | 2012-04-19 | 2012-04-19 | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101175413A CN102631430B (en) | 2012-04-19 | 2012-04-19 | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631430A CN102631430A (en) | 2012-08-15 |
| CN102631430B true CN102631430B (en) | 2013-11-13 |
Family
ID=46616109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101175413A Expired - Fee Related CN102631430B (en) | 2012-04-19 | 2012-04-19 | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631430B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548119A (en) * | 2003-05-24 | 2004-11-24 | 毛友昌 | Yiqingwan bolus and its prepn |
| CN1698757A (en) * | 2005-05-09 | 2005-11-23 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical preparation for treating upper respiratory tract infection and its preparation process and quality control method |
| KR100643191B1 (en) * | 2004-06-22 | 2006-11-10 | 이상국 | Compositions comprising Rhei Rhizoma, Scutellaria baicalensis, and Coptis chinensis for inhibition of reendothelialization and prevention and treatment of cardio vascular diseases |
| CN1876039A (en) * | 2005-05-09 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical composition for treating upper respiratory tract infection, its preparation process and quality control method |
| CN101002849A (en) * | 2007-01-30 | 2007-07-25 | 中国人民解放军第三○二医院 | Traditional Chinese medicine extractive or tablet for treating hepatitis, and its preparing method |
| CN102085332A (en) * | 2011-01-13 | 2011-06-08 | 冯安华 | Medicament for treating early ascites due to cirrhosis |
| CN102379935A (en) * | 2010-09-03 | 2012-03-21 | 高雄医学大学 | Composition for preventing or treating diseases caused by arteriosclerosis |
-
2012
- 2012-04-19 CN CN2012101175413A patent/CN102631430B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548119A (en) * | 2003-05-24 | 2004-11-24 | 毛友昌 | Yiqingwan bolus and its prepn |
| KR100643191B1 (en) * | 2004-06-22 | 2006-11-10 | 이상국 | Compositions comprising Rhei Rhizoma, Scutellaria baicalensis, and Coptis chinensis for inhibition of reendothelialization and prevention and treatment of cardio vascular diseases |
| CN1698757A (en) * | 2005-05-09 | 2005-11-23 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical preparation for treating upper respiratory tract infection and its preparation process and quality control method |
| CN1876039A (en) * | 2005-05-09 | 2006-12-13 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical composition for treating upper respiratory tract infection, its preparation process and quality control method |
| CN101002849A (en) * | 2007-01-30 | 2007-07-25 | 中国人民解放军第三○二医院 | Traditional Chinese medicine extractive or tablet for treating hepatitis, and its preparing method |
| CN102379935A (en) * | 2010-09-03 | 2012-03-21 | 高雄医学大学 | Composition for preventing or treating diseases caused by arteriosclerosis |
| CN102085332A (en) * | 2011-01-13 | 2011-06-08 | 冯安华 | Medicament for treating early ascites due to cirrhosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631430A (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102302544B (en) | Chinese medicinal composition for preventing and treating hepatic fibrosis | |
| CN101194984A (en) | Chinese medicine composition for treating early and medium-term chronic renal failure | |
| CN102670642A (en) | Traditional Chinese compound medicament for treating fatty liver disease | |
| CN102631430B (en) | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN102423468B (en) | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof | |
| CN107854656B (en) | Lipid-lowering traditional Chinese medicine composition and preparation method and application thereof | |
| CN104840962B (en) | A kind of pharmaceutical composition for improving high fat high-carbonhydrate diet complication and its application | |
| CN107041899B (en) | Medicine for treating insulin resistance, preparation method and application | |
| CN107744571B (en) | Pharmaceutical composition for improving vascular endothelial dysfunction and preparation method and application thereof | |
| CN102836237B (en) | YANG invigorating also five controlled slow-release preparations and preparation method thereof of a kind of entirety release | |
| CN101890063A (en) | Chinese medicament for reducing blood sugar and preparation method thereof | |
| CN102641357B (en) | Medicament for treating hypertension and preparation method thereof | |
| CN103055176A (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN101085191B (en) | Pulse engendendering active component extraction and its preparation | |
| CN101269115B (en) | Cardiac and cerebral vascular disease treating medicament preparation and method for preparing the same | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN102008588B (en) | Medicine composition for curing hepatic encephalopathy and hepatitis B | |
| CN102357171A (en) | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof | |
| CN104107352A (en) | Chinese herbal medicine for blood pressure reducing, and administration method thereof | |
| CN103565956B (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN1686238A (en) | Medicinal composition for treating diabetes | |
| CN114272354B (en) | Traditional Chinese medicine composition for preventing and improving senile dementia, preparation method and application thereof | |
| CN102018940B (en) | Composition with lactogenic effect and preparation method and application thereof | |
| CN102512481B (en) | Common threewingnut root capsules and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131113 Termination date: 20180419 |